Genetron Holdings Limited announced changes to the Company's Board of Directors and executive team. Dr. Chao Tang and Mr. Shan Fu have been appointed as Directors of the Company, effective immediately. Dr. Chao Tang will replace Dr. Weiwu He, who has served as Chairman of the Board since May 2015. Mr. Shan Fu will replace Mr. Weidong Liu, who has served as Director since November 2019. Both Dr. He and Mr. Liu resigned from the Board due to personal reasons. In recognition of Dr. He's invaluable contributions to the Company during his tenure of services, the Board has appointed him as Chairman Emeritus of the Board. The Board has also appointed Mr. Sizhen Wang as the new Chairman of the Board. In addition, effective June 30, 2021, Mr. Kevin Ying Hong will become a Senior Advisor to Genetron Health. Mr. Hong has been a significant contributor to the growth and success of Genetron Health and his expertise can continue to help the company, following his resignation as COO from the company for personal reasons. In addition, effective June 30, 2021, Mr. Kevin Ying Hong will become a Senior Advisor to Genetron Health. Mr. Hong has been a significant contributor to the growth and success of Genetron Health and his expertise can continue to help the company, following his resignation as COO from the company for personal reasons. Mr. Shan Fu has served as joint Chief Executive Officer and the Greater China Chief Executive Officer of Vivo Capital LLC since October 2013.